Please assess the completion status of the following clinical trial:

Trial Title: Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥18~* History of and currently experiencing angina at least 3 times per week~* No obstructive coronary artery disease~* On stable medical therapy for 30 days prior to enrollment~* Must agree to use a reliable and acceptable method of contraception for the duration of participation~* Written informed consent~Exclusion Criteria:~* Myocardial infarction within 90 days~* Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or CABG)~* Diagnosis of other specific cardiac disease~* Must meet LVEF and GFR requirements~* Current use of coumadin or DOACs~* Hypersensitivity to G-CSF, apheresis or study product components~* Positive for HIV, hepatitis B or hepatitis C~* Active inflammatory or autoimmune disease, or chronic immunosuppressive state~* Drug abuse~* Pregnant or lactating~* Malignant neoplasm within 5 years~* History of Sickle Cell Disease~* Participation in another clinical study within 90 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous CD34 cells (Type: EXPERIMENTAL): Open label active treatment arm. Subjects receive autologous CD34 cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).